CAM Group Holding A S cut its position in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 51.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 97,407 shares of the specialty pharmaceutical company’s stock after selling 101,500 shares during the period. CAM Group Holding A S’s holdings in Eagle Pharmaceuticals were worth $3,778,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of EGRX. State Street Corp increased its position in shares of Eagle Pharmaceuticals by 64.3% in the first quarter. State Street Corp now owns 629,493 shares of the specialty pharmaceutical company’s stock worth $25,489,000 after buying an additional 246,262 shares during the last quarter. Cormorant Asset Management LLC increased its position in shares of Eagle Pharmaceuticals by 25.0% in the first quarter. Cormorant Asset Management LLC now owns 500,000 shares of the specialty pharmaceutical company’s stock valued at $20,250,000 after buying an additional 100,000 shares in the last quarter. LaSalle Street Capital Management LLC acquired a new position in shares of Eagle Pharmaceuticals during the second quarter valued at approximately $304,000. Bank of Montreal Can acquired a new position in shares of Eagle Pharmaceuticals during the second quarter valued at approximately $5,356,000. Finally, American Century Companies Inc. increased its position in shares of Eagle Pharmaceuticals by 6.1% in the second quarter. American Century Companies Inc. now owns 114,901 shares of the specialty pharmaceutical company’s stock valued at $4,457,000 after buying an additional 6,567 shares in the last quarter.
Shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) traded up 3.50% during mid-day trading on Tuesday, hitting $65.07. The stock had a trading volume of 429,927 shares. The stock has a market capitalization of $1.02 billion, a P/E ratio of 333.69 and a beta of 1.15. The stock has a 50 day moving average of $64.20 and a 200-day moving average of $49.87. Eagle Pharmaceuticals Inc. has a 52 week low of $33.02 and a 52 week high of $102.48.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.09. The company earned $40.90 million during the quarter, compared to analysts’ expectations of $43.55 million. Eagle Pharmaceuticals had a return on equity of 3.44% and a net margin of 3.45%. Eagle Pharmaceuticals’s revenue for the quarter was up 581.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.53) earnings per share. On average, equities research analysts predict that Eagle Pharmaceuticals Inc. will post $3.21 earnings per share for the current year.
Several research analysts have commented on the company. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $91.00 price target on shares of Eagle Pharmaceuticals in a research report on Saturday. Mizuho lifted their price target on Eagle Pharmaceuticals from $47.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 16th. Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 4th. TheStreet raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Finally, RBC Capital Markets reaffirmed an “outperform” rating and issued a $80.00 price target (up from $78.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, September 22nd. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $89.24.
In related news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $60.77, for a total transaction of $1,516,150.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 18.80% of the company’s stock.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc. (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.